FDA Restrictions on Compound GLP-1 Medications This regulatory action follows the FDA's February 2025 declaration that the semaglutide shortage is officially "resolved." For compounded tirzepatide (Zepbound), the deadline was earlier - March 2025
Those numbers mean most patients will not develop persistent arrhythmias, but if palpitations are accompanied by chest pain, fainting, or breathlessness, treat them as urgent
Summary first published in September 2012, authored by Peter Renner and Markus Horneber
they are managing hundreds
Mounjaro has authorised prescribing information that healthcare professionals use when selecting and adjusting treatment
She explains how appetite suppression can lead to low protein, vitamin deficiencies, and dehydration, all of which directly impact your skin, hair, and nails